Home Hero
Home Hero

For your patients’ severe
eosinophilic asthma

Help bring
back balance

By preventing exacerbations
& by reducing daily OCS dose

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.


Hospital icon

Exacerbation reduction

Trial 2 53% reduction in exacerbations vs placebo1*
61% reduction in exacerbations requiring hospitalization/ED visit vs placebo*

Real-world study: Interim analysis at 12 months2
Associated with

Reduction image

Secondary objective. Results are descriptive.

See study limitations

Pill icon

OCS reduction

Trial 3: Greater percent reduction in daily OCS dose (Weeks 20-24) while maintaining asthma control vs placebo (P=0.008; Primary Endpoint.)3

Reduction in daily OCS dose3

OCS reduction image

Results are descriptive.
Sensitivity analysis to the primary endpoint.

Lung icon

Long-term data

4.5-year open-label study:
Exacerbation rate 0.68/year (Secondary Endpoint)4§

Associated with

Long-term exacerbation reduction image

Results are descriptive. Median duration 3.8 years.

Real-world study: Prespecified interim analysis of a 2-year prospective, observational cohort study (N=368). Secondary objective (shown above): Post-exposure NUCALA 0.27/year vs baseline 1.14/year; rate ratio 0.23 (95% CI: 0.18, 0.30). Primary objective (Exacerbations/year): Post-exposure NUCALA 1.43 vs baseline 4.63 (69% reduction; rate ratio 0.31; 95% CI: 0.27, 0.35). Results are descriptive. Study limitations: May not reflect final results. Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.2

§4.5-year open-label study: Assessed safety, immunogenicity, and efficacy of NUCALA (N=347). Secondary endpoint: Mean exacerbations/year: 0.68 (95% CI: 0.60, 0.78) with NUCALA + asthma controller in all patients; based on exacerbations reported from the time a patient enrolled until study withdrawal (median duration 3.8 years). Rate prior to study start was 1.74.4 Results are descriptive.

*Trial 2: 32-week placebo controlled study (N=576) Primary endpoint: Frequency of exacerbations. NUCALA+SOC 0.83/year, placebo+SOC 1.74/year, P<0.001. Secondary endpoint: Frequency of exacerbations requiring hospitalization and/or ED visit. NUCALA+SOC 0.08/year, placebo+SOC 0.20/year, P=0.02.1

Trial 3: 24-week placebo-controlled study (N=135); Sensitivity analysis to the primary endpoint. NUCALA+SOC 95% CI: 20.0, 75.0; placebo+SOC 95% CI: -20, 33.3.3 Results are descriptive.

The targeted therapy for 4 eosinophil-driven diseases

NUCALA is for the:

See Important Safety Info

Checklist icon

Get your patients started with NUCALA

Steps for accessing NUCALA and other helpful resources for your SEA patients and practice

See patient access & support

NUCALA Autoinjector icon

Administering NUCALA 

NUCALA gives appropriate patients the option to self-administer at home.

See SEA dosing & administration

CI=confidence interval; ED=emergency department; IL=interleukin; MOA=mechanism of action; OCS=oral corticosteroid; SOC=standard of care.